Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

作者：Jeffrey Aaron Berinstein, Taylor A. Karl, Anish A Patel, Michael Todd Dolinger, Terrence A. Barrett, Waseem N. Ahmed, Benjamin H. Click, Calen A. Steiner, David T. Dulaney, Jake Levine, Syed Adeel Hassan, Courtney L. Perry, Deborah R. Flomenhoft, Ryan C. Ungaro, Elliot M. Berinstein, Jessica L. Sheehan, Shirley Cohen‐Mekelburg, Randolph E. Regal, Ryan William Stidham, Shrinivas Bishu, Jean‐Frédéric Colombel, Peter Higgins · 发表于：The American Journal of Gastroenterology · 年份：2024 · DOI：10.14309/ajg.0000000000002674 · 被引用次数：54 · 研究领域：Inflammatory Bowel Disease、Microscopic Colitis、Diverticular Disease and Complications

INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.